Brought to you by 
Supernus nets $48.8mm in initial public offering
03 May 2012
Executive Summary
Supernus Pharmaceuticals Inc. (CNS diseases) has netted $48.8mm in its initial public offering of 10mm shares at $5. Existing shareholders bought 6mm of the shares. Last month, the company announced terms of 5.8mm shares at $12-14, then increased the number of shares, to 11mm, and lowered the price to $5.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Supernus nets $48.8mm in initial public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice